1.Research on Comprehensive Budget Management Strategy of Tertiary Public Hospitals in the Context of High-Quality Development
Ziyu ZHAO ; Qian WANG ; Jinhu GUO ; Rui LU ; Yingjie FU ; Jian WANG
Chinese Health Economics 2025;44(10):90-94
Based on the Political Economic Social Technological(PEST)-Strengths Weakness Opportunity Threats(SWOT)model,by sorting out the macro-environmental factors such as politics,economy,society and technology,and combining the internal strengths and weaknesses of the hospital as well as the external opportunities and threats,it puts forward the strategies to optimize the comprehensive budget management.It is found that hospitals face problems in total budget management such as disconnection between budgeting and strategy,and low level of informatization,but they also have advantages such as resource optimization and support for decision-making.The external environment provides opportunities such as health insurance reform and financing channel expansion,while there are threats such as industry competition and data security.It is suggested to improve the budget management level and promote the high-quality development of hospitals by expanding funding sources,strengthening cost control,and promoting the integration of industry and finance.
2.Guideline for Adult Weight Management in China
Weiqing WANG ; Qin WAN ; Jianhua MA ; Guang WANG ; Yufan WANG ; Guixia WANG ; Yongquan SHI ; Tingjun YE ; Xiaoguang SHI ; Jian KUANG ; Bo FENG ; Xiuyan FENG ; Guang NING ; Yiming MU ; Hongyu KUANG ; Xiaoping XING ; Chunli PIAO ; Xingbo CHENG ; Zhifeng CHENG ; Yufang BI ; Yan BI ; Wenshan LYU ; Dalong ZHU ; Cuiyan ZHU ; Wei ZHU ; Fei HUA ; Fei XIANG ; Shuang YAN ; Zilin SUN ; Yadong SUN ; Liqin SUN ; Luying SUN ; Li YAN ; Yanbing LI ; Hong LI ; Shu LI ; Ling LI ; Yiming LI ; Chenzhong LI ; Hua YANG ; Jinkui YANG ; Ling YANG ; Ying YANG ; Tao YANG ; Xiao YANG ; Xinhua XIAO ; Dan WU ; Jinsong KUANG ; Lanjie HE ; Wei GU ; Jie SHEN ; Yongfeng SONG ; Qiao ZHANG ; Hong ZHANG ; Yuwei ZHANG ; Junqing ZHANG ; Xianfeng ZHANG ; Miao ZHANG ; Yifei ZHANG ; Yingli LU ; Hong CHEN ; Li CHEN ; Bing CHEN ; Shihong CHEN ; Guiyan CHEN ; Haibing CHEN ; Lei CHEN ; Yanyan CHEN ; Genben CHEN ; Yikun ZHOU ; Xianghai ZHOU ; Qiang ZHOU ; Jiaqiang ZHOU ; Hongting ZHENG ; Zhongyan SHAN ; Jiajun ZHAO ; Dong ZHAO ; Ji HU ; Jiang HU ; Xinguo HOU ; Bimin SHI ; Tianpei HONG ; Mingxia YUAN ; Weibo XIA ; Xuejiang GU ; Yong XU ; Shuguang PANG ; Tianshu GAO ; Zuhua GAO ; Xiaohui GUO ; Hongyi CAO ; Mingfeng CAO ; Xiaopei CAO ; Jing MA ; Bin LU ; Zhen LIANG ; Jun LIANG ; Min LONG ; Yongde PENG ; Jin LU ; Hongyun LU ; Yan LU ; Chunping ZENG ; Binhong WEN ; Xueyong LOU ; Qingbo GUAN ; Lin LIAO ; Xin LIAO ; Ping XIONG ; Yaoming XUE
Chinese Journal of Endocrinology and Metabolism 2025;41(11):891-907
Body weight abnormalities, including overweight, obesity, and underweight, have become a dual public health challenge in Chinese adults: overweight and obesity lead to a variety of chronic complications, while underweight increases the risks of malnutrition, sarcopenia, and organ dysfunction. To systematically address these issues, multidisciplinary experts in endocrinology, sports science, nutrition, and psychiatry from various regions have held multiple weight management seminars. Based on the latest epidemiological data and clinical evidence, they expanded the guideline to include assessment and intervention strategies for underweight, in addition to the core content of obesity management. This guideline outlines the etiological mechanisms, evaluation methods, and multidimensional management strategies for overweight and obesity, covering key areas such as diagnosis and assessment, medical nutrition therapy, exercise prescription, pharmacological intervention, and psychological support. It is intended to provide a scientific and standardized approach to weight management across the adult population, aiming to curb the rising prevalence of obesity, mitigate complications associated with abnormal body weight, and improve nutritional status and overall quality of life.
3.Construction of usage evaluation model of large-scale medical equipment based on analytic hierarchy process
Lu-lu WAN ; Jian-guo WANG ; De-chang QIN
Chinese Medical Equipment Journal 2025;46(8):86-90
Objective To construct an evaluation model for the use of large-scale medical equipment based on the analytic hierarchy process(AHP).Methods The indicators of the evaluation model were determined with considerations on the req-uirements of Accreditation Standard for Tertiary Hospitals(2022 edition),performance assessment standards of municipal departments for large-scale medical equipment in medical institutions over the years,the present situation of medical insti-tutions,key indexes for performance evaluation and the basic operational efficiency of the equipment.The evaluation model was established by calculating the weights of the indicators with AHP and performing the consistency test.The utilization of four CT devices in some hospital in a certain year was used as an example to comprehensively evaluate the rationality and feasibility of the model.Results There were 5 first-level indicators and 14 second-level indicators involved in the large-scale medical equipment usage evaluation model.The first-level indicators were made up of the usage,social benefits,functional utilization,economic benefits,scientific research and teaching benefits,with the weights of 45.156%,21.090%,12.113%,15.983%,and 5.657%,respectively,with all the first-level and second-level indicators passing the consistency test.The analysis of levels indicator weights showed the indicators affecting the operational efficiency included positive rate,expected work rate,utilization rate,etc.Comprehensive evaluation indicated the model was consistent with the traditional evaluation modes when used for ranking the equipment usage.Conclusion The AHP-based large-scale medical equipment usage evaluation model with high practicality facilitates the decision of medical institutions for the utilization,allocation and management of specialized medical equipment.[Chinese Medical Equipment Journal,2025,46(8):86-90]
4.Study on the effectiveness and safety of a novel intravascular shock wave balloon for pre-treatment of severe coronary artery calcification lesions
Rui-tao ZHANG ; Zhen-yu TIAN ; Yong ZENG ; Guo-sheng FU ; Li XU ; Jian LIU ; Jian-ping LI ; Zhi-hui ZHANG ; Xin-qun HU ; Xiang CHENG ; Wen LU ; Ming CUI ; Yi-da TANG
Chinese Journal of Interventional Cardiology 2025;33(2):61-70
Objective To evaluate the efficacy and safety of a novel intravascular lithotripsy(IVL)balloon—Vesscrack shockwave balloon—for vascular preparation before stent implantation in patients with severe coronary artery calcification(CAC).Methods This was a prospective,single-arm,multicenter study conducted in China from June 2022 to October 2022.Patients with severe CAC were treated with the Vesscrack shockwave balloon for lesion preparation,followed by drug-eluting stent(DES)implantation.Of these,33 patients underwent optical coherence tomography(OCT).The primary endpoint was procedural success,defined as successful stent implantation with residual stenosis≤30%and the absence of in-hospital major adverse events,including cardiac death,target vessel-related myocardial infarction,or target lesion revascularization.Results A total of 170 patients[mean age:(65.9±7.9)years,116 males]were enrolled.After treatment with IVL and DES,the minimum lumen diameter increased significantly compared to baseline[(2.34±0.40)mm vs.(0.95±0.33)mm,P<0.001],the degree of stenosis was significantly reduced[(13.24±6.60)%vs.(65.18±10.59)%,P<0.001].Procedural success was achieved in 100%of cases,and device success was 98.8%.The 30-day patient-related cardiovascular clinical composite endpoint(POCE)rate was 0.0,with no target lesion failure,no confirmed or potential thrombotic events were observed.The shockwave energy generator demonstrated excellent stability and ease of use.Among the 33 patients assessed with OCT,after IVL intervention,the maximum calcified area of the lumen[(3.51±1.51)mm2 vs.(2.85±1.80)mm2,P<0.001],and the minimum lumen area within the target lesion[(3.08±1.04)mm2 vs.(2.02±0.75)mm2,P<0.001],and after DES intervention,the luminal area of the largest calcified site[(6.59±1.64)mm2 vs.(2.85±1.80)mm2,P<0.001]and the minimum luminal area within the target lesion[(6.19±1.45)mm2 vs.(2.02±0.75)mm2,P<0.001]were significantly increased,and the differences were statistically significant.Conclusions The Vesscrack shockwave balloon is effective and safe for vascular preparation in patients with severe CAC prior to stent implantation.It achieves significant calcified plaque modification,high procedural success rates,and minimal complications.
5.Predictive Value of Baseline Extracellular Volume for Therapeutic Cardiac Response in Light Chain Cardiac Amyloidosis
Yang LU ; Jingyi LI ; Yubo GUO ; Yining WANG ; Jian LI ; Zhuang TIAN
Chinese Circulation Journal 2025;40(6):583-590
Objectives:This study aims to explore the value of the baseline extracellular volume(ECV)measured by cardiac magnetic resonance(CMR)in predicting cardiac response in patients with light chain cardiac amyloidosis(AL-CA)after treatment.Methods:This single-center retrospective cohort study included AL-CA patients diagnosed between May 2020 and March 2023.Baseline ECV measurement and other relevant parameters were derived from CMR.Therapeutic cardiac response was assessed through serial measurements of N-terminal pro-B-type natriuretic peptide(NT-proBNP).Complete recovery was defined as achieving NT-proBNP≤350 pg/ml post-treatment.Patients demonstrating>60%reduction from baseline NT-proBNP without attaining complete response criteria were classified as very good partial recovery.Those showing 31%-60%decreases from baseline NT-proBNP without meeting the threshold for very good partial recovery were qualified as partial recovery,while≤30%reductions from baseline were considered as non-recovery.The study evaluated two endpoints:the initial emergence of any cardiac recovery(encompassing partial recovery,very good partial recovery,or complete recovery)and the subsequent attainment of optimal cardiac recovery(encompassing partial recovery,very good partial recovery,or complete recovery).The patients were divided into two groups based on whether they experienced cardiac recovery at the end of follow-up:the recovery group(n=24,comprising 7 with partial recovery,14 with very good partial recovery,and 3 with complete recovery)and the non-recovery group(n=16).Cox Proportional hazards regression models were used to analyse the impact of baseline ECV on the cardiac recovery.The Kaplan-Meier method and log-rank test were used to assess and compare the probability and timing of cardiac recovery between different baseline ECV groups.Results:Among the 40 patients,28(70%)were male,with a mean age of(58?±?8)years.32 patients(80%)had the λ subtype of AL-CA.During a median follow-up of 568(155,1 049)days,15 patients showed partial cardiac recovery at 60 days post-treatment,and 3 patients achieved very good partial cardiac recovery;by 720 days of treatment and until the end of follow-up,3 patients achieved complete cardiac recovery.Multivariate Cox regression analysis revealed that baseline ECV(HR=0.937,95%CI:0.879-0.999,P=0.045)and daratumumab-based regimens(HR=3.279,95%CI:1.098-9.796,P=0.033)were significant predictors of the initial cardiac recovery.Similarly,baseline ECV(HR=0.931,95%CI:0.867-1.000,P=0.048)and daratumumab-based regimens(HR=3.132,95%CI:1.052-9.319,P=0.040)were also independent predictors for the best cardiac recovery.Kaplan-Meier analysis demonstrated that patients with baseline ECV<54%achieved an earlier first cardiac recovery than those with baseline ECV≥54%(log-rank P=0.014)and the group with baseline ECV<55%were more likely to achieve the best cardiac recovery compared to those with baseline ECV≥55%(log-rank P=0.006).Conclusions:Baseline ECV measured by CMR can serve as an independent predictor of cardiac recovery in AL-CA patients after treatment.Lower baseline ECV levels are associated with a faster and more favorable cardiac recovery.The daratumumab-based regimens demonstrated superior cardiac recovery outcomes.
6.Expert consensus on integrated diagnosis and treatment techniques for oropharyngeal squamous cell carcinoma
Wei SHANG ; Haoyue XU ; Zongxuan HE ; Xiaoying LI ; Haijun LU ; Xiaohong ZHAN ; Dapeng HAO ; Yan SUN ; Wei GUO ; Zhangui TANG ; Guoxin REN ; Zhijun SUN ; Jian MENG ; Jie ZHANG ; Jichen LI ; Yue HE ; Chunjie LI ; Jianhua WEI ; Lizheng QIN ; Yaowu YANG ; Qing XI ; Wei WU ; Kai YANG ; Bing HAN ; Lingxue BU ; Shuangyi WANG ; Kai SONG ; Jiaqi ZHU ; Hongyu HAN ; Yu KONG ; Jieying LI ; Man HU ; Mingjin XU ; Moyi SUN
Journal of Practical Stomatology 2025;41(6):725-736
In recent decades,the incidence of human papillomavirus(HPV)-associated oropharyngeal squamous cell carcinoma(OPSCC)has shown a marked increase.Significant changes have also occurred in the OPSCC diagnosis and treatment paradigm.Deter-mining HPV status prior to treatment is now essential,and radiotherapy/chemotherapy,immunotherapy,and minimally invasive surgical techniques have progressively emerged as key modalities for managing OPSCC.However,alongside these paradigm shifts,a comprehen-sive technical consensus guiding the entire diagnostic and therapeutic process for OPSCC patients is currently lacking.Given China's large population base and the rising incidence of OPSCC,an expert panel convened to develop a clinical technical consensus on OPSCC diagno-sis and management tailored to China's specific context.This consensus aims to further enhance and standardize understanding of OPSCC management techniques among relevant healthcare professionals.
7.Clinical analysis of recurrent ovarian cancer with malignant bowel obstruction
Xiang ZHAO ; Hongjie GUO ; Jing LU ; Ying YAN ; Jian WANG
Chinese Journal of Postgraduates of Medicine 2025;48(9):774-778
Objective:To analyze the abdominal CT types, surgical methods, obstruction recurrence rate and postoperative chemotherapy rate in patients with recurrent ovarian cancer and malignant bowel obstruction (MBO).Methods:The clinical data of 43 patients with recurrent ovarian cancer and MBO from September 30, 2021 to December 31, 2024 in the Fourth Affiliated Hospital of Nanjing Medical University were retrospectively analyzed. Intestinal surgical plans were determined based on abdominal CT classification and intraoperative conditions. The imaging data, surgical conditions, occurrence of severe complications within 30 d after surgery and mortality within 30 d after surgery were recorded. The patients were followed up once a month until February 28, 2025, and the obstruction recurrence rate and chemotherapy rate were recorded.Results:Among the 43 patients, the abdominal CT types were as follows: 9 cases (20.9%) of isolated recurrence type, 25 cases (58.2%) of non-infiltrating proximal small intestine type, 8 cases (18.6%) of infiltrating proximal small intestine type, and 1 case (2.3%) of other types. Two patients underwent exploratory laparotomy; 41 patients completed the intended surgical treatment, including 5 cases of intestinal intubation ostomy, 2 cases of pull-through ostomy, 2 cases of bypass surgery, 26 cases of resection + ostomy, and 6 cases of resection + anastomosis. After surgery, 19 cases (43.2%) resumed partial enteral nutrition, and 16 cases (37.2%) achieved complete enteral nutrition. The incidence of severe postoperative complications within 30 d after surgery was 9.3% (4/43). Obstructive symptoms such as abdominal distension were relieved in 41 cases (95.3%). The mortality within 30 d after surgery was 7.0% (3/43), the obstruction recurrence rate was 7.0% (3/43), and the chemotherapy rate was 76.7% (33/43). By the end of follow-up, 7 patients were still alive.Conclusions:Recurrent ovarian cancer complicated by MBO is a high-risk disease. Identifying patients who may benefit can improve the relief rate of obstructive symptoms such as abdominal distension, reduce the obstruction recurrence rate, and increase the chemotherapy rate.
8.Effect of leflunomide combined with belimumab on activity index and renal function in patients with lupus nephritis
Jian GUO ; Jing LIU ; Xin JIN ; Lu JIN
Journal of China Medical University 2025;54(7):603-607
Objective To investigate the effects of leflunomide combined with belimumab on the activity index and renal function of patients with lupus nephritis(LN).Methods A total of 82 patients with LN admitted to Tangshan Gongren Hospital from January 2022 to January 2024 were selected as study subjects and randomly divided into two groups:the combination group(belimumab+leflunomide treatment)and the control group(leflunomide treatment),with 41 patients in each group.Renal function indicators(blood urea nitrogen(BUN),serum creatinine(sCr),uric acid(UA),and 24-hour urine protein),disease activity[Systemic Lupus Erythematosus Disease Activity Index(SLEDAI)score],laboratory indicators(anti-double-stranded DNA antibody,anti-ds-DNA;C-reactive protein,CRP;tumor necrosis factor α,TNF-α),efficacy,and safety were compared before and after treatment between the two groups.Results After treatment,the levels of BUN,sCr,UA,and 24-hour urine protein in the combination group were significantly lower than those in the con-trol group(P<0.05).Furthermore,the SLEDAI score,anti-ds-DNA,CRP,and TNF-α levels in the combination group were also lower than those in the control group(P<0.05).The total effective rate in the combination group(97.56%)was higher than that in the control group(85.37%,P=0.048),despite no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Leflunomide combined with belimumab treatment for LN can effectively improve clinical efficacy,reduce disease activity,alleviate inflammation,enhance immune function,and improve renal function,with a certain level of safety,thus making the regimen highly valuable for clinical application and promotion.
9.Research progress on the role and mechanism of high mobility group box protein 1 after spinal cord injury
Xin XUE ; Chang-zheng YIN ; Jin-hui CHEN ; Lu-rong HUANG ; Xin ZHENG ; Yi-min LI ; Guo-bao XIAO ; Ping ZHANG ; Jian-hua ZHAO
Journal of Regional Anatomy and Operative Surgery 2025;34(10):918-923
High mobility group box protein 1(HMGB1)is one of the most widely expressed protein member in the HMGs family,which is well known for its involvement in the body inflammatory response.Previous researches have found that it plays a significant role in cell migration,immune identification and neuroprotection.Spinal cord injury is a disease that causes severe damage to the nervous system,and neural circuits are disrupted after a spinal cord injury,which leads to many conditions including ischemia and hypoxia,inflammatory responses,demyelinating lesions,and glial scar formation that are detrimental to nerve regeneration and repair,making it one of the most difficult diseases to treat in the modern spinal surgery field.HMGB1 is upregulated after spinal cord injury,thereby regulating neuroinflam-matory responses,and participating in the neuronal apoptosis,promoting neuronal regeneration,and inducing neural stem cell differentiation and migration,which plays an important role in the process of neural function recovery.This paper summarizes the structure and function of HMGB1,as well as its role in spinal cord injury,in order to provide direction for founding therapeutic target for neurological function recovery after spinal cord injury.
10.Expert consensus on holistic integrative management of oropharyngeal squamous cell carcinoma
Moyi SUN ; Zongxuan HE ; Qianwei NI ; Xiaoying LI ; Lin KONG ; Qing XI ; Wei GUO ; Zhangui TANG ; Guoxin REN ; Zhijun SUN ; Jian MENG ; Jie ZHANG ; Jichen LI ; Yue HE ; Chunjie LI ; Lizheng QIN ; Kai YANG ; Bing HAN ; Yan SUN ; Haijun LU ; Xiaohong ZHAN ; Dapeng HAO ; Kai SONG ; Haoyue XU ; Lingxue BU ; Jieying LI ; Man HU ; Mingjin XU ; Yun LI ; Wei SHANG
Journal of Practical Stomatology 2025;41(3):293-304
Oropharyngeal squamous cell carcinoma(OPSCC)is a malignant tumor originating from the squamous epithelium of the oro-pharyngeal mucosa,accounting for more than 90%of oropharyngeal malignancies.In recent years,human papillomavirus(HPV)infec-tion has become one of the primary etiological factors of oropharyngeal squamous carcinoma.The incidence of HPV-associated oropharyn-geal squamous carcinoma has been rising annually,with a noticeable trend toward younger populations,posing a significant threat to hu-man health.Due to the distinct biological behavior and clinical characteristics of HPV-associated oropharyngeal squamous carcinoma com-pared to its non-HPV-related counterpart,the diagnostic and treatment strategies for oropharyngeal squamous carcinoma have undergone substantial changes.Prevention and screening for oropharyngeal squamous carcinoma are of critical importance.The diagnostic and treat-ment process involves multi-disciplinary collaboration,including oral and maxillofacial surgery,otolaryngology,head and neck surgery,oncology,radiology and pathology.Based on evidence from clinical practice,a comprehensive,integrated diagnostic and therapeutic ap-proach has been established,centered around the concept of"prevention,screening,diagnosis,treatment,and rehabilitation",covering the entire patient lifecycle and providing a valuable reference for clinical practice.

Result Analysis
Print
Save
E-mail